Inotek raises $21 million to continue development of glaucoma treatment

Inotek Pharmaceuticals has closed a financing round that raised $21 million to help further development and study of a novel eye drop designed to increase aqueous outflow via the trabecular meshwork, according to a news release.A recently completed phase 2 study of trabodenoson, given as monotherapy, demonstrated efficacy similar to that of prostaglandins, the release said. The funding will help finance a phase 2 study of trabodenoson combined with latanoprost to treat patients whose IOP is not well controlled by latanoprost alone.

Full Story →